Parkside Financial Bank & Trust Sells 1,476 Shares of Bristol-Myers Squibb (NYSE:BMY)

Parkside Financial Bank & Trust lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 8.0% during the fourth quarter, Holdings Channel reports. The firm owned 17,017 shares of the biopharmaceutical company’s stock after selling 1,476 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Bristol-Myers Squibb were worth $873,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BMY. RFG Advisory LLC lifted its holdings in shares of Bristol-Myers Squibb by 13.7% during the 3rd quarter. RFG Advisory LLC now owns 16,952 shares of the biopharmaceutical company’s stock valued at $984,000 after buying an additional 2,046 shares during the period. Onyx Bridge Wealth Group LLC increased its stake in shares of Bristol-Myers Squibb by 25.3% in the 3rd quarter. Onyx Bridge Wealth Group LLC now owns 7,226 shares of the biopharmaceutical company’s stock worth $419,000 after purchasing an additional 1,457 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its stake in Bristol-Myers Squibb by 58.3% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 4,967 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 1,830 shares in the last quarter. BTC Capital Management Inc. increased its stake in Bristol-Myers Squibb by 7.9% in the 3rd quarter. BTC Capital Management Inc. now owns 92,514 shares of the biopharmaceutical company’s stock worth $5,370,000 after buying an additional 6,746 shares in the last quarter. Finally, Advisors Management Group Inc. ADV increased its stake in Bristol-Myers Squibb by 19.9% in the 3rd quarter. Advisors Management Group Inc. ADV now owns 7,717 shares of the biopharmaceutical company’s stock worth $448,000 after buying an additional 1,281 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of research analyst reports. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. Finally, Bank of America downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $61.18.

Bristol-Myers Squibb Stock Performance

NYSE BMY traded up $0.08 on Tuesday, reaching $49.22. 4,335,160 shares of the company’s stock traded hands, compared to its average volume of 15,461,111. The firm has a market cap of $99.76 billion, a price-to-earnings ratio of 12.76, a P/E/G ratio of 1.48 and a beta of 0.39. The stock has a 50 day moving average price of $51.22 and a 200-day moving average price of $51.38. Bristol-Myers Squibb has a fifty-two week low of $47.58 and a fifty-two week high of $70.93. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The business had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.82 earnings per share. Equities research analysts predict that Bristol-Myers Squibb will post 6.63 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.88%. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.